| This week's sponsor is INC Research. | |  | |
Top Stories Tuesday, October 4, 2016 Buoyed by its recent, and controversial, FDA approval for its Duchenne drug Exondys 51 (eteplirsen), Sarepta has signed a pact potentially worth more than half a billion dollars with the U.K.’s Summit Therapeutics, giving it rights to its Duchenne candidate in Europe and elsewhere. Monday, October 3, 2016 Small cap Dynavax bounced almost 20% on news that the FDA has requested information regarding its application for its hepatitis B vaccine. Tuesday, October 4, 2016 Daiichi Sankyo has partnered with startup AgonOx to develop novel drugs against an undisclosed immuno-oncology target. Tuesday, October 4, 2016 A month after Mylan and Biocon saw the EMA accept their marketing application for a copycat version of Roche’s major blockbuster cancer med Herceptin (trastuzumab)--the first to do so--Samsung Bioepis says it too has now notched that regulatory milestone as the companies race to market. Tuesday, October 4, 2016 Altor and NantKwest have signed a new research collab that will see the two work in tandem by combining their early-stage experimental meds in the hope they can hit more cancer targets together. Tuesday, October 4, 2016 The world’s largest CRO and one of the biggest healthcare data and consultancy firms have become one major $19 billion 50,000-strong company this week as QuintilesIMS comes into life. Tuesday, October 4, 2016 ConvaTec, a medical products company that makes wound care dressings and colostomy bags, is looking to raise $1.8 billion in a public offering on the London Stock Exchange in what could be London's largest public offering of the year. | This week's sponsor is FierceBiotech. | |  | FierceBiotech Presents:
A Half Day Executive Summit
Hosted at the Royal Society of Medicine, London
R&D Challenges: A UK Perspective
Cocktail Reception to follow
27 October, 2016
Register Now! |
| | | Riptide Bioscience has set up a three-year cooperative R&D deal with the National Cancer Institute with a focus on its early work in pancreatic cancer. Statement Neurological focused New York biotech Acorda Therapeutics has seen the departure of its CFO Michael Rogers, who will serve as a consultant to the firm for the rest of the year. Release Swiss biotech Turing Pharmaceuticals has set up a toxoplasmosis R&D collab with Washington University in St. Louis as it looks to find new treatments for the infection. Statement Lyon, France-based Theranexus has been given an orphan tag from the FDA for its lead candidate THN102, which is being tested for narcolepsy. Release California cancer biotech Five Prime Therapeutics has started the Phase Ib part of an I/O combo test of its experimental cabiralizumab together with Bristol-Myers' PD-1 cancer drug Opdivo. Statement | |
|
Resources Presented by: Covance The role of health economic data has never been more important. Presented by: Covance Leading manufacturers increasingly employ stakeholder research early in development to better identify the needs of patients and providers. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. | 
